About DermaSensor
DermaSensor is a health technology company that has developed an innovative, AI-powered, handheld medical device for the early detection of skin cancer. The device is designed for use by primary care physicians and other healthcare professionals who are not dermatologists, aiming to improve access to quality skin cancer care and aid in timely clinical decision-making. It utilizes a combination of optical spectroscopy and artificial intelligence to non-invasively assess suspicious skin lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma. The device works by shining light bursts on a lesion, capturing scattered light spectra, and using proprietary AI algorithms to analyze cellular and sub-cellular features to assess malignancy risk in seconds, providing an objective ‘Monitor’ or ‘Investigate’ result. This technology is intended to be used in conjunction with a physician’s clinical assessment and not as a standalone diagnostic tool or screening device.
The DermaSensor device has demonstrated high sensitivity (96-100%) in detecting the three most common skin cancers in published studies and has received FDA Class II De Novo clearance in early 2024, making it the first automated skin cancer detection device of its kind available for primary care use in the U.S. Its use has been shown to reduce missed skin cancer referrals by 30-52%. By providing immediate, objective risk assessments at the point of care, DermaSensor aims to streamline the skin exam process, minimize the need for unnecessary biopsies and specialist referrals, and ultimately enhance early detection rates, leading to better patient outcomes. The company emphasizes its role in empowering frontline providers, particularly in areas with limited access to dermatologists, to make more informed decisions regarding suspicious lesions.
Focus Areas
Business Intelligence
| Technology | Cloud-native, edge computing, AI operating system, optical spectroscopy, machine learning |
What Physicians Need to Know
For physicians, DermaSensor offers an FDA-cleared, AI-powered, non-invasive tool to enhance skin cancer detection at the point of care. It provides an immediate 'Investigate Further' or 'Monitor' result with 96% sensitivity across all three common skin cancers, aiding in more confident and accurate referral decisions. This can significantly reduce missed cancer referrals (by 30% to 52%) and potentially unnecessary biopsies or specialist visits for benign lesions. The device is intended to complement, not replace, clinical judgment and visual assessment, and is indicated for patients aged 40 and above with lesions already assessed as suspicious. Reimbursement assistance and coding guidance are available to help integrate the device into practice.
DermaSensor's device is a standalone, handheld medical device that integrates into existing clinical workflows by providing immediate, objective risk assessment at the point of care. While specific EMR/EHR integrations are not explicitly detailed in the provided information, the device's secure wireless connectivity enables easy data transfer to companion software, which provides clear information to guide clinicians. The company also offers product education and workflow support to facilitate seamless integration into practice.
What the Web Says
DermaSensor is a health technology company that has developed an FDA-cleared, handheld AI-powered device for the non-invasive detection of all common skin cancers. The device is intended for use by non-dermatologist physicians to provide an objective risk assessment of suspicious skin lesions. The company aims to improve early detection of skin cancer and reduce missed cancer referrals.
Overall: PositiveStrengths
- High sensitivity in detecting skin cancers (96%).
- Reduces missed cancer referrals by 50%.
- Provides objective and immediate risk assessment for suspicious lesions.
- Easy to use and integrates into existing clinical workflows.
- Can increase physician confidence in evaluating skin lesions.
- Cost-effective solution for skin cancer screening in primary care settings.
Limitations
- Low specificity, meaning it may flag many benign lesions for further investigation.
- Does not diagnose cancer or replace a biopsy.
- Not for at-home use or screening healthy skin.
- Additional expense due to a subscription-based plan.
- Limited information on employer reviews from Glassdoor, G2, or Capterra.
- Some Reddit users express a 'wait and see' attitude regarding long-term accuracy.
Based on reviews from: The Healthcare Discovery Team, DermaSensor Official Website, Dermatoscopes.com, Reddit, TIME, MassDevice, The Healthcare Technology Report, Indeed.com, Zippia, The Brink, WJTV.com
Last updated: 2026-10-21
Videos
News, demos, and interviews about DermaSensor.
Videos load interactively. If none appear, search YouTube for DermaSensor →
Press & Coverage
Frequently Asked Questions
Related Companies
A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]
The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]
Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]